



| Report Number: | 23-009670/D008.R000 |
|-----------------|---------------------|
| Report Date: | 08/18/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 08/15/23 11:03 |

_ _ _

| Customer: | Bayou City Hemp Oklahoma |
|-------------------|--------------------------|
| Product identity: | V08Cm30811 |
| Client/Metrc ID: | |
| Laboratory ID: | 23-009670-0002 |

| Summary | |
|---------|--|
| | |

| Analyte | Result (%) | | | |
|---------|------------|-----------------------------------------|-----------------|------------------------|
| ∆8-THC | 79.2 | | CBD-Total | <loq< td=""></loq<> |
| ∆8-THCV | 0.197 | | | |
| CBT | 0.0879 | • 8-THC | THC-Total | <loq< td=""></loq<> |
| | | 8-THCV CBT | (Reported in pe | rcent of total sample) |
| | | | | |
| | | | | |

Page 1 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 23-009670/D008.R000 |
|-----------------|---------------------|
| Report Date: | 08/18/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 08/15/23 11:03 |

| Customer: | Bayou City Hemp Oklahoma 102 Avenue N. Idabel Oklahoma 74745 United States of America (USA) |
|----------------------|------------------------------------------------------------------------------------------------------|
| Product identity: | V08Cm30811 |
| Client/Metrc ID: | |
| Sample Date: | |
| Laboratory ID: | 23-009670-0002 |
| Evidence of Cooling: | No |
| Temp: | 27.2 °C |
| Relinquished by: | client |

Sample Results

| Potency | Method: J AOAC 2018 | 5 V98-6 (mod |) ^þ Units % | Batch: 2310117 | Analyze: 8/16/23 | 10:15:00 PM |
|------------------------|--------------------------|--------------|------------------------|----------------|------------------|-------------|
| Analyte | As Dry Received weigh | LOQ | Notes | | | |
| CBC | < LOQ | 0.0692 | | | | |
| CBC-A | < LOQ | 0.0692 | | | | |
| CBC-Total | < LOQ | 0.130 | | | | 8-THC |
| CBD | < LOQ | 0.0692 | | | | 8-THCV |
| CBD-A | < LOQ | 0.0692 | | | | CBT |
| CBD-Total | < LOQ | 0.130 | | | | |
| CBDV | < LOQ | 0.0692 | | | | |
| CBDV-A | < LOQ | 0.0692 | | | | |
| CBDV-Total | < LOQ | 0.129 | | | | |
| CBE | < LOQ | 0.0692 | | | | |
| CBG | < LOQ | 0.0692 | | | | |
| CBG-A | < LOQ | 0.0692 | | | | |
| CBG-Total | < LOQ | 0.129 | | | | |
| CBL | < LOQ | 0.0692 | | | | |
| CBL-A | < LOQ | 0.0692 | | | | |
| CBL-Total | < LOQ | 0.130 | | | | |
| CBN | < LOQ | 0.0692 | | | | |
| CBT | 0.0879 | 0.0692 | | | | |
| $\Delta 10$ -THC-9R | < LOQ | 0.0692 | | | | |
| $\Delta 10$ -THC-9S | < LOQ | 0.0692 | | | | |
| $\Delta 10$ -THC-Total | < LOQ | 0.138 | | | | |
| $\Delta 8$ -THC | 79.2 | 0.692 | | | | |
| ∆8-THCV | 0.197 | 0.0692 | | | | |
| ∆9-THC | < LOQ | 0.0692 | | | | |
| delta-9-THCP | < LOQ | 0.0692 | | | | |
| exo-THC | < LOQ | 0.0692 | | | | |
| THC-A | < LOQ | 0.0692 | | | | |
| THC-Total | < LOQ | 0.130 | | | | |
| THCV | < LOQ | 0.0692 | | | | |
| THCV-A | < LOQ | 0.0692 | | | | |
| | < LOQ | 0.129 | | | | |
| THCV-Total | 79.5 | 0.123 | | | | |

Page 2 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 23-009670/D008.R000 |
|-----------------|---------------------|
| Report Date: | 08/18/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 08/15/23 11:03 |

| Potency | Method: J AOAC 2015 VS | 98-6 (mod) ^p Units % | Batch: 2310117 | Analyze: 8/16/23 10:15:00 PM |
|---------|---------------------------|---------------------------------|----------------|------------------------------|
| Analyte | As Dry Received weight | LOQ Notes | | |
| | | | | |

Page 3 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





Report Number: 23-009670/D008.R000 Report Date: 08/18/2023 **ORELAP#:** OR100028 Purchase Order: **Received:** 08/15/23 11:03

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

^b = ISO/IEC 17025:2017 accredited method.

Units of Measure

% = Percentage of sample % wt = $\mu g/g$ divided by 10,000

Approved Signatory

Derrick Tanner General Manager

www.columbialaboratories.com

Page 4 of 8

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made





| Report Number: | 23-009670/D008.R000 |
|-----------------|---------------------|
| Report Date: | 08/18/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 08/15/23 11:03 |

Revision: 4 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| J AOAC 2015 V98-6 | 5 | | | | E | atch ID: 23 | 10117 | | |
|------------------------------------------------------------------------------|--------|--------|----------------------------|-------|-------------|-------------|----------------------|--------------------------|-------|
| Laboratory Control | Sample | | | | | | | | |
| Analyte | LCS | Result | Spike | Units | % Rec | Lin | nits | Evaluation | Notes |
| CBDVA | 2 | 0.0761 | 0.0718 | % | 106 | 80.0 | - 120 | Acceptable | |
| CBDV | 2 | 0.0742 | 0.0708 | % | 105 | 80.0 | - 120 | Acceptable | |
| BE | 2 | 0.0840 | 0.0805 | % | 104 | 80.0 | - 120 | Acceptable | |
| CBDA | 1 | 0.0790 | 0.0776 | % | 102 | 90.0 | - 110 | Acceptable | |
| CBGA | 1 | 0.0781 | 0.0774 | % | 101 | 80.0 | - 120 | Acceptable | |
| CBG | 1 | 0.0811 | 0.0794 | % | 102 | 80.0 | - 120 | Acceptable | |
| CBD | 1 | 0.0829 | 0.0812 | % | 102 | 90.0 | - 110 | Acceptable | |
| HCV | 2 | 0.0520 | 0.0513 | % | 101 | 80.0 | - 120 | Acceptable | |
| 18THCV | 2 | 0.0622 | 0.0627 | % | 99.1 | 80.0 | - 120 | Acceptable | |
| HCVA | 2 | 0.0815 | 0.0715 | % | 114 | 80.0 | - 120 | Acceptable | |
| BN | 1 | 0.0789 | 0.0810 | % | 97.4 | | - 120 | Acceptable | |
| xo-THC | 2 | 0.0706 | 0.0718 | % | 98.3 | | - 120 | Acceptable | |
| 9THC | 1 | 0.0769 | 0.0796 | % | 96.7 | | - 110 | Acceptable | |
| 18THC | 1 | 0.0713 | 0.0750 | % | 95.0 | | - 110 | Acceptable | |
| S-d10THC | 1 | 0.0772 | 0.0816 | % | 94.5 | 80.0 | - 120 | Acceptable | |
| BL | 2 | 0.0719 | 0.0718 | % | 100 | | - 120 | Acceptable | |
| R-d10THC | 1 | 0.0701 | 0.0745 | % | 94.1 | | - 120 | Acceptable | |
| CBC | 2 | 0.0711 | 0.0736 | % | 96.7 | | - 120 | Acceptable | |
| НСА | 1 | 0.0720 | 0.0763 | % | 94.3 | 90.0 | - 110 | Acceptable | |
| BCA | 2 | 0.0794 | 0.0750 | % | 106 | | - 120 | Acceptable | |
| BLA | 2 | 0.121 | 0.115 | % | 105 | | - 120 | Acceptable | |
| 9THCP | 2 | 0.0688 | 0.0746 | % | 92.2 | | - 120 | Acceptable | |
| BT | 2 | 0.0613 | 0.0725 | % | 84.5 | 80.0 | - 120 | Acceptable | |
| Method Blank | - | 0.0013 | 0.0725 | 70 | 84.5 | 80.0 | - 120 | Acceptable | |
| Analyte | R | esult | LOQ | | Units | Lin | nits | Evaluation | Notes |
| CBDVA | < | LOQ | 0.0698 | 1 | % | < 0.0 | 0698 | Acceptable | |
| CBDV | < | LOQ | 0.0698 | | % | < 0.0 | 0698 | Acceptable | |
| CBE | < | LOQ | 0.0698 | | % | < 0.0 | 0698 | Acceptable | |
| BDA | < | LOQ | 0.0698 | | % | < 0.0 | 0698 | Acceptable | |
| BGA | | LOQ | 0.0698 | | % | < 0.0 | 0698 | Acceptable | |
| BG | < | LOQ | 0.0698 | | % | < 0.0 | 0698 | Acceptable | |
| CBD | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| HCV | < | LOQ | 0.0698 | | % | < 0.0 | 0698 | Acceptable | |
| 18THCV | | LOQ | 0.0698 | 1 | % | < 0.0 | | Acceptable | |
| HCVA | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| BN | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| xo-THC | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| ІЭТНС | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| ISTHC | | 100 | 0.0698 | | % | | 0698 | Acceptable | |
| | | 100 | 0.0698 | | % | < 0.0 | | Acceptable | |
| S-d10THC | < | | | 1 | % | | 0698 | Acceptable | |
| S-d10THC CBL | | LOQ | 0.0698 | | | | | | |
| S-d10THC CBL R-d10THC | < | | | | | < 0.0 | 0698 | | |
| 9S-d10THC CBL PR-d10THC CBC | < | LOQ | 0.0698 | | % | < 0.0 | | Acceptable | |
| DS-d10THC CBL DR-d10THC CBC THCA | < | LOQ | 0.0698 0.0698 | | % % | < 0.0 | 0698 | Acceptable | |
| ISTHC S-d10THC EBL SR-d10THC CBC FHCA CBCA CBCA CBLA | < | | 0.0698 0.0698 0.0698 | | % % % | < 0.0 | 0698 0698 | Acceptable Acceptable | |
| 9S-d10THC CBL 9R-d10THC CBC CHCA | | LOQ | 0.0698 0.0698 | | % % | < 0.0 | 0698 0698 0698 | Acceptable | |

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

Units of Measure: % - Percent

Page 5 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 23-009670/D008.R000 |
|-----------------|---------------------|
| Report Date: | 08/18/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 08/15/23 11:03 |

Revision: 4 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| J AOAC 2015 V98-6 | Batch ID: 2310117 | | | | | | | | |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|--------|-------|-------|--------|------------|-------|--|
| Sample Duplicate | Sample ID: 23-009667-0001 | | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes | |
| CBDVA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBDV | 0.345 | 0.344 | 0.0755 | % | 0.194 | < 20 | Acceptable | | |
| CBE | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBDA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBGA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBG | 0.162 | 0.161 | 0.0755 | % | 0.577 | < 20 | Acceptable | | |
| CBD | 93.6 | 95.2 | 0.0755 | % | 1.63 | < 20 | Acceptable | | |
| THCV | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| d8THCV | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| THCVA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBN | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| exo-THC | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| d9THC | 0.181 | 0.179 | 0.0755 | % | 1.28 | < 20 | Acceptable | | |
| d8THC | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| 9S-d10THC | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBL | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| 9R-d10THC | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBC | 0.160 | 0.156 | 0.0755 | % | 2.67 | < 20 | Acceptable | | |
| THCA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBCA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBLA | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| d9THCP | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |
| CBT | <loq< td=""><td><loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.0755</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.0755 | % | NA | < 20 | Acceptable | | |

ND - None Detected at or above MRL RPD - Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure:

% - Percent

Page 6 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 23-009670/D008.R000 | | |
|-----------------|---------------------|--|--|
| Report Date: | 08/18/2023 | | |
| ORELAP#: | OR100028 | | |
| Purchase Order: | | | |
| Received: | 08/15/23 11:03 | | |



Page 7 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





23-009670/D008.R000 **Report Number: Report Date:** 08/18/2023 ORELAP#: OR100028 **Purchase Order:** 08/15/23 11:03 **Received:**

Explanation of QC Flag Comments:

| Code | Explanation | | | | | |
|------|---------------------------------------------------------------------------------------------|--|--|--|--|--|
| Q | Matrix interferences affecting spike or surrogate recoveries. | | | | | |
| Q1 | Quality control result biased high. Only non-detect samples reported. | | | | | |
| Q2 | Quality control outside QC limits. Data considered estimate. | | | | | |
| Q3 | Sample concentration greater than four times the amount spiked. | | | | | |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. | | | | | |
| Q5 | Spike results above calibration curve. | | | | | |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. | | | | | |
| R | Relative percent difference (RPD) outside control limit. | | | | | |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. | | | | | |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. | | | | | |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. | | | | | |
| LOQ2 | Quantitaion level raised due to matrix interference. | | | | | |
| В | Analyte detected in method blank, but not in associated samples. | | | | | |
| B1 | The sample concentration is greater than 5 times the blank concentration. | | | | | |
| B2 | The sample concentration is less than 5 times the blank concentration. | | | | | |

 www.columbialaboratories.com
 Page 8 of 8

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430